The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia

Background: Type 2 diabetes is associated with early development of endothelial dysfunction. Patients present with typical dyslipidemia (predominantly high levels of triglycerides [TG] and low levels of high-density lipoprotein cholesterol [HDL-C]) or mixed hypercholesterolemia (high levels of low-density lipoprotein cholesterol [LDL-C] and TG with low HDL-C). Normal levels include LDL-C <100 mg/dL, TG <135 mg/dL, and HDL-C > 40 mg/dL for men and >50 mg/dL for women. Objective: To determine the effects of 8 weeks administration of fenofibrate on inflammatory markers, metabolic parameters, and endothelial dysfunction. Methods: We administered micronized fenofibrate (Laboratories Fourneir S.A Dijon, France) daily for 8 weeks to 40 dyslipidemic, type 2 diabetes patients with equal numbers in each arm of the typical or mixed dyslipidemia groups. Noninvasive endothelial function assessments were performed and serum inflammatory markers obtained before and after treatment. Results: The typical group demonstrated significantly greater TG reduction and HDL-C increment, ie, 56 vs, 21.3 (P